比较SGLT2抑制剂与DPP-4抑制剂在2型糖尿病及不同基线HbA1c水平患者中的有效性和安全性
这项新使用者比较有效性及安全性研究纳入144 614例商业保险的2型糖尿病成人,起始SGLT2抑制剂(n=60 523)或DPP-4抑制剂(n=84 091)。经1:1倾向评分匹配87 274例后,SGLT2抑制剂组改良MACE发生率17.13 vs 20.18/1000人年(HR 0.85;95%CI 0.75-0.95),心衰住院3.68 vs 8.08/1000人年(HR 0.46;95%CI 0.35-0.57),平均随访8个月,各HbA1c水平间无治疗效应异质性。SGLT2抑制剂增加生殖器感染和糖尿病酮症酸中毒风险,降低急性肾损伤风险;除HbA1c 7.5%-9%亚组生殖器感染风险更明显(HR 3.10;95%CI 2.68-3.58)外,其余结果按HbA1c水平一致。
要点
- 与DPP-4抑制剂相比,SGLT2抑制剂降低改良MACE风险(HR 0.85;95%CI 0.75-0.95)和心衰住院风险(HR 0.46;95%CI 0.35-0.57),平均随访8个月。
- SGLT2抑制剂的心血管获益不随基线HbA1c水平改变(各HbA1c水平间无治疗效应异质性)。
- SGLT2抑制剂增加生殖器感染和糖尿病酮症酸中毒风险,降低急性肾损伤风险。
- HbA1c 7.5%-9%亚组中SGLT2抑制剂相关生殖器感染风险更明显(IR 68.5 vs 22.8/1000人年;HR 3.10;95%CI 2.68-3.58)。
适用人群与场景
- 商业保险的2型糖尿病成人,基线有2型糖尿病诊断且治疗启动前3个月内至少有1次HbA1c实验室结果。
- 共144 614例,平均(SD)年龄62(12.4)岁,54%为男性。
诊断标准与关键阈值
- 基线HbA1c分层:<7.5%(44 099例)、7.5%-9%(52 986例)、>9%(47 529例)。
研究设计与关键结果
- 研究设计:新使用者比较有效性及安全性研究,纳入144 614例起始SGLT2抑制剂(n=60 523)或DPP-4抑制剂(n=84 091)的2型糖尿病成人,控制128个协变量。
- 倾向评分匹配:87 274例1:1匹配,其中HbA1c<7.5% 24 052例、7.5%-9% 32 290例、>9% 30 932例。
- 改良MACE:SGLT2抑制剂 vs DPP-4抑制剂发生率17.13 vs 20.18/1000人年,HR 0.85(95%CI 0.75-0.95),RD -3.02(95%CI -5.23至-0.80)。
- 心衰住院:SGLT2抑制剂 vs DPP-4抑制剂发生率3.68 vs 8.08/1000人年,HR 0.46(95%CI 0.35-0.57),RD -4.37(95%CI -5.62至-3.12),平均随访8个月。
- 各HbA1c水平间无治疗效应异质性。
- 安全性:SGLT2抑制剂增加生殖器感染和糖尿病酮症酸中毒风险,降低急性肾损伤风险。
- HbA1c 7.5%-9%亚组生殖器感染:SGLT2抑制剂 vs DPP-4抑制剂发生率68.5 vs 22.8/1000人年,HR 3.10(95%CI 2.68-3.58),RD 46.22(95%CI 40.54-51.90)。
证据类型、等级与局限
- 证据类型:新使用者比较有效性及安全性研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在2型糖尿病成人中,起始SGLT2抑制剂相比DPP-4抑制剂与改良MACE和心衰住院风险降低相关,且不随基线HbA1c水平改变;同时生殖器感染和糖尿病酮症酸中毒风险增加,急性肾损伤风险降低。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Sodium-glucose cotransporter 2 inhibitor (SGLT2i) therapy has been associated with cardiovascular benefits and a few adverse events; however, whether the comparative effectiveness and safety profiles vary with differences in baseline hemoglobin A1c (HbA1c) levels is unknown.
OBJECTIVE: To compare cardiovascular effectiveness and safety of treatment with SGLT2i vs dipeptidyl peptidase 4 inhibitor (DPP-4i) in adults with type 2 diabetes (T2D) (1) overall and (2) at varying baseline HbA1c levels.
DESIGN, SETTING, AND PARTICIPANTS: A new-user comparative effectiveness and safety research study was conducted among 144 614 commercially insured adults, initiating treatment with SGLT2i or DPP-4i and with a recorded T2D diagnosis at baseline and at least 1 HbA1c laboratory result recorded within 3 months before treatment initiation.
INTERVENTIONS: The intervention consisted of the initiation of treatment with SGLT2i or DPP-4i.
MAIN OUTCOMES AND MEASURES: Primary outcomes were a composite of myocardial infarction, stroke, or all-cause death (modified major adverse cardiovascular events [MACE]) and hospitalization for heart failure (HHF). Safety outcomes were hypovolemia, fractures, falls, genital infections, diabetic ketoacidosis (DKA), acute kidney injury (AKI), and lower-limb amputation. Incidence rate (IR) per 1000 person-years, hazard ratios (HR) and rate differences (RD) with their 95% CIs were estimated controlling for 128 covariates.
RESULTS: A total of 144 614 eligible adults (mean [SD] age, 62 [12.4] years; 54% male participants) with T2D initiating treatment with a SGLT2i (n = 60 523) or a DPP-4i (n = 84 091) were identified; 44 099 had an HbA1c baseline value of less than 7.5%, 52 986 between 7.5% and 9%, and 47 529 greater than 9%. Overall, 87 274 eligible patients were 1:1 propensity score-matched: 24 052 with HbA1c less than 7.5%; 32 290 with HbA1c between 7.5% and 9%; and 30 932 with HbA1c greater than 9% (to convert percentage of total hemoglobin to proportion of total hemoglobin, multiply by 0.01). The initiation of SGLT2i vs DPP-4i was associated with a reduction in the risk of modified MACE (IR per 1000 person-years 17.13 vs 20.18, respectively; HR, 0.85; 95% CI, 0.75-0.95; RD, -3.02; 95% CI, -5.23 to -0.80) and HHF (IR per 1000 person-years 3.68 vs 8.08, respectively; HR, 0.46; 95% CI, 0.35 to 0.57; RD -4.37; 95% CI, -5.62 to -3.12) over a mean follow-up of 8 months, with no evidence of treatment effect heterogeneity across the HbA1c levels. Treatment with SGLT2i showed an increased risk of genital infections and DKA and a reduced AKI risk compared with DPP-4i. Findings were consistent by HbA1c levels, except for a more pronounced risk of genital infections associated with SGLT2i for HbA1c levels of 7.5% to 9% (IR per 1000 person-years 68.5 vs 22.8, respectively; HR, 3.10; 95% CI, 2.68-3.58; RD, 46.22; 95% CI, 40.54-51.90).
CONCLUSIONS AND RELEVANCE: In this comparative effectiveness and safety research study among adults with T2D, SGLT2i vs DPP-4i treatment initiators had a reduced risk of modified MACE and HHF, an increased risk of genital infections and DKA, and a lower risk of AKI, regardless of baseline HbA1c.
参考来源
- D'Andrea E, Wexler DJ, Kim SC, et al. Comparing Effectiveness and Safety of SGLT2 Inhibitors vs DPP-4 Inhibitors in Patients With Type 2 Diabetes and Varying Baseline HbA1c Levels. JAMA Intern Med. 2023. PMID: 36745425. doi:10.1001/jamainternmed.2022.6664
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。